Inventor · disambiguated record
Charles Dumontet
Also filed as: DUMONTET CHARLES
3 granted patents·11 pending applications·1 citations·filing 2007–2018
47Inventor score
Files withHOFFMANN LA ROCHE3DUMONTET CHARLES2ROCHE GLYCART AG2BOUMENDJEL AHCENE1CENTRE NAT DE LA RECH SCIENTIFIQUE-CNRS1
Top patents by PatentIndex Score
14 records- 0164US2009246197A1Combination therapy of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc)DUMONTET CHARLES·Filed 2009·Application pending·0 cites
- 0262US2016000911A1Combination therapy of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxity (adcc)ROCHE GLYCART AG·Filed 2014·Application pending·0 cites
- 0359US2014065134A1Combination therapy of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxity (adcc)ROCHE GLYCART AG·Filed 2013·Application pending·0 cites
- 0458US9783541B25′-nucleotidase inhibitors and therapeutic uses thereofCENTRE NAT DE LA RECH SCIENTIFIQUE-CNRS·Filed 2014·Granted Oct 10, 2017·1 cites·14 claims
- 0555US2012301459A1Combination therapy of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc)DUMONTET CHARLES·Filed 2011·Application pending·0 cites
- 0655US2011177067A1Combination therapy of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc)HOFFMANN LA ROCHE·Filed 2011·Application pending·0 cites
- 0753US2010310581A1Combination therapy of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc)HOFFMANN LA ROCHE·Filed 2010·Application pending·0 cites
- 0849US2012045523A1Combination of a tlr3 ligand and a chemotherapy agent which acts on the intrinsic "apoptosis" pathway in the treatment of cancerLEBECQUE SERGE·Filed 2009·Application pending·0 cites
- 0943US2017114146A1Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2016·Application pending·0 cites
- 1043US2014363500A1Use of an antibody and a particulate immunomodulatorEPITARGET AS·Filed 2014·Application pending·0 cites
- 1141US12433838B2Liposomal formulation of bacterial lipopolysaccharide combined with a cytotoxic agent, and use thereof in anti-tumour therapyINST NAT SANTE RECH MED·Filed 2018·Granted Oct 7, 2025·0 cites·15 claims
- 1241US9896415B2Chalcone derivatives having an anti-allergic activityUNIV CLAUDE BERNARD LYON·Filed 2014·Granted Feb 20, 2018·0 cites·11 claims
- 1337US2009182058A1Novel Chalcone Derivatives With Antimitotic ActivityBOUMENDJEL AHCENE·Filed 2007·Application pending·0 cites
- 1432US2014038883A1Novel azacoumarin derivatives having mdr pump inhibiting activityDOLEANS-JORDHEIM ANNE·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Charles Dumontet files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →